ARTICLE | Finance
Vaccine dream team
Why investors flocked to a €42 million series B for cancer vaccine play Nouscom
November 10, 2017 11:02 PM UTC
An experienced vaccine development team, vector technology that has been tested in humans and two neoantigen programs poised to enter the clinic helped Nouscom AG land a €42 million ($48.8 million) series B round.
Abingworth led the tranched round, which closed on Nov. 6, and was joined by fellow new investor 5AM Ventures and existing investors LSP and Versant Ventures. Details of the tranches are undisclosed...
BCIQ Company Profiles